Digital Therapeutics (DTx)

Digital therapeutics (DTX)

For leaders, innovators and change-makers in this industry.

Companies leading this conference
conference agenda

Day 1 - November 30th

Time Session Name Speakers Session description
9:00 - 9:05 Opening Remarks Shafi Ahmed , Chief Medical Officer, Medical Realities
9:05 - 10:00 Keynote Address Shane Tickell, Vice Chair of Health and Social Care, Tech UK
Adam Thomas, CIO, Dudley Group NHS FT
Will Smart (formerly NHS CIO 2016 – 2019), Global Director External Relations, Dedalus

10:00 - 11:15

Panel Discussion: A Pharma Perspective - Deploying DTx Partnerships to go Beyond the Pill

Johannes Munding, Associate Director Digital Health Solutions , Novartis
Susanne Gruber, VP Pharma Partnerships, Sidekick Health
Stephane Wolf, WW Head Digital Solutions, Ophthalmology , Novartis
Thomas Geuenich, Commercial Director, Germany , Teladoc Health
Dr. Klaus Suwelack, New Business Development & Innovation Management , Janssen Germany
Nikos Green, Senior Venture Architect & PO Neuroscience , RoX Health GmbH
Moderator - Ralf-Gordon Jahns, Managing Director , Research2Guidance
Covid-19 has drastically accelerated the adoption of digital health solutions. The increased utilization of digital therapeutics has shown to ease the burden faced by the healthcare system during the pandemic. This shift towards digital adoption has put pressure on pharma to innovate beyond their traditional approaches.

1. What should DTx/Pharma companies look for when establishing partnerships?
2. What are the challenges being seen in these partnerships?
3. How are partnerships being used to drive DTx adoption?
4. What does the future of DTx partnerships potentially look like?
11:15 - 12:00 Panel Discussion: The Changing Landscape - DTx & Virtual Clinical Trial Solution Impact
Adam Samson, Senior Director, Clinical Operations and Customer Success , Curebase
Markus Dahlem, CEO , Newsenselab
Isabel Cassidy-Soto, Digital Health Consultant , Research2Guidance
Moderator - Ralf-Gordon Jahns, Managing Director, Research2Guidance
The pandemic has accelerated the rate at which real-world data and digital tools have been adopted to conduct clinical trials. The pandemic coupled with the appropriate technologies have caused a fundamental shift towards decentralized virtual clinical trials. Resulting in rich data sets invaluable for researching a wide range of interventions, variables, and specific patient populations.
1. What are the differences between traditional and virtual clinical trials?
2. How do DTx solutions assist in running virtual/hybrid clinical trials?
3. How do we assess the value of DTx solutions through clinical trials?
4. What are the current challenges being experienced in this space?
12:00 - 12:30

Neural Digital Therapeutics - The Next Wave of Precision Medicine

Emil Hewage, Co-Founder & CEO, BIOS Health DNA sequencing opened up a new field of precision medicine; now, AI is doing the same for the nervous system. The brain sends our bodies vast amounts of information every second of every day, but currently there is no data-driven insight into the nervous system, meaning feedback on treatment efficacy can take months. The next wave of healthcare will be driven by neural interfaces and AI that, for the first time, can read and write the body's neural ‘code' to understand and correct those signals in real-time. Neural digital therapies will use read/write software to create more precise and effective pharmaceuticals, digital biomarkers, and even software-delivered treatments direct to the nervous system.
12:30 - 13:00 The Emergence of Digital Health Ecosystems Tobias Silberzahn, Partner, McKinsey
13:00 - 14:30 Lunch and Networking
14:30 - 15:00 Fireside Chat Big Health
15:00 - 15:30 Mechanism of Action for DTx and the Science of Allostasis Chris Wasden, Head of Pharma Speciality Solutions & Corporate Strategy, Happify

Day 2 - December 1st - Stage 3

Time Session Name Speakers Session description
9:00 - 9:45 Session Announced Soon Galen Growth
9:45 - 10:05 Addressing the burden of systemic inflammation with digital therapeutics Pierre Bonnat, CEO , Neurodigit X
10:05 - 10:30

Can avatars play a role in the future of healthcare?

Alex Merckx, Director of Marketing and Partnerships, Cognitant
10:30 - 11:30 Coffee Break and Networking
11:30 - 12:45

SAPiO Showcase

11:30 - 11:45 - Orbia (virtual)
11:45 - 12:00 - Vyasa (Virtual)
12:00 - 12:15 - Tag n Trac (Virtual)
12:15 - 12:30 - Chekkit (In-person)
12:30 - 12:45 - Laura (In-person)
12:45 - 13:00 Session Announced Soon Thomas Oliver, Founder/CEO, Omnos
13:00 - 14:30 Lunch and Networking
14:30 - 15:00 DTX Panel discussion. Presented by the Founders of DTx Impact, an innovative new DTx advisory service Tony Kypreos, Advisory Council Member & Venture Partner, UN Sustainable Development Goals
Professor Shafi Ahmed, Chief Medical Officer, Medical Realities
Dr. Tal Mahmud, Advisory Board Member, Digital Healthcare Show & GP Partner
15:00 - 15:30 Session Announced Soon Bene Studio
15:30 - 16:15 Session Announced Soon Galen Growth

Co-curated by: Research2guidance

Research2Guidance is a management consultancy specializing in the digital health market. We support established healthcare companies and start-ups with insights, strategic advice, and hands-on partnership building.

We do this by providing market and competitor insights (research) and strategy advice (guidance). We facilitate partnerships creation between best-in-class innovators and established healthcare companies, helping them align their service offerings and business models.
We strive for excellence in all we do. Our consultants are 100% dedicated to digital health.
Based in Berlin, we work on projects around the world. Supporting traditional healthcare companies like pharmaceutical, health insurance, med-tech companies, medical institutions, start-ups, and enterprises that want to enter the healthcare market using digital-enabled business models and solutions.


Digital Therapeutics (DTx) are transforming the standard of care and potentially closing the gap in prevention and treatment.

This fast-growing billion USD market and the opportunity it presents to improve personalized health outcomes at scale has ignited interest from different health care stakeholders, including pharma, who have started to explore this space through investments and strategic partnerships.


Some of the questions that the session will address are:

  1. What will it take to scale DTx across different countries?
  2. Which business models may prove to be most successful?
  3. How can pharma leverage technology to improve the real-world performance drugs and create stand-alone DTx intervention?
  4. What will it take for payers to adopt DTx, and how will they pay?
Who is this conference for?

We invite you to be part of and engage in inspiring discussions with our speakers, innovators, and change-makers in this industry.

No matter what you specialise in, whether your company is already building groundbreaking digital therapeutics, or you hope to invest in those who do, or if you are simply want to find the best solutions for your clients and patients, this event is for you.

why should i attend this conference?

Join us to hear first-hand cases and examples from leading global DTx, pharma, insurers, and digital innovators.

As they demonstrate new commercial models to accelerate clinical trials, novel value chains, service offerings, patient engagement strategies, and strategic partnerships that have led to market success or lessons learned, as well as different business and reimbursement models.